Status:
COMPLETED
Varenicline Observational Investigation In The Cessation of Smoking
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being...
Detailed Description
Sampling Method Details: Patients as they come to surgeries for smoking cessation treatment.
Eligibility Criteria
Inclusion
- The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes.
- The patients must be willing to make an attempt to stop smoking.
Exclusion
- All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
567 Patients enrolled
Trial Details
Trial ID
NCT00669240
Start Date
November 1 2007
End Date
August 1 2009
Last Update
July 23 2015
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Alleur, Belgium, 4432
2
Pfizer Investigational Site
Beerse, Belgium, 2340
3
Pfizer Investigational Site
Braine-le-Comte, Belgium, 7090
4
Pfizer Investigational Site
Brussels, Belgium, 1070